318 related articles for article (PubMed ID: 11737582)
1. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.
White KE; Carn G; Lorenz-Depiereux B; Benet-Pages A; Strom TM; Econs MJ
Kidney Int; 2001 Dec; 60(6):2079-86. PubMed ID: 11737582
[TBL] [Abstract][Full Text] [Related]
2. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.
Shimada T; Muto T; Urakawa I; Yoneya T; Yamazaki Y; Okawa K; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Endocrinology; 2002 Aug; 143(8):3179-82. PubMed ID: 12130585
[TBL] [Abstract][Full Text] [Related]
3. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency.
Bai XY; Miao D; Goltzman D; Karaplis AC
J Biol Chem; 2003 Mar; 278(11):9843-9. PubMed ID: 12519781
[TBL] [Abstract][Full Text] [Related]
4. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.
White KE; Jonsson KB; Carn G; Hampson G; Spector TD; Mannstadt M; Lorenz-Depiereux B; Miyauchi A; Yang IM; Ljunggren O; Meitinger T; Strom TM; Jüppner H; Econs MJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):497-500. PubMed ID: 11157998
[TBL] [Abstract][Full Text] [Related]
5. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
Imel EA; Hui SL; Econs MJ
J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
[TBL] [Abstract][Full Text] [Related]
6. FGF23 is processed by proprotein convertases but not by PHEX.
Benet-Pagès A; Lorenz-Depiereux B; Zischka H; White KE; Econs MJ; Strom TM
Bone; 2004 Aug; 35(2):455-62. PubMed ID: 15268897
[TBL] [Abstract][Full Text] [Related]
7. Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Ichikawa S; Gray AK; Padgett LR; Allen MR; Clinkenbeard EL; Sarpa NM; White KE; Econs MJ
Endocrinology; 2014 Oct; 155(10):3891-8. PubMed ID: 25051439
[TBL] [Abstract][Full Text] [Related]
8. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.
Farrow EG; Yu X; Summers LJ; Davis SI; Fleet JC; Allen MR; Robling AG; Stayrook KR; Jideonwo V; Magers MJ; Garringer HJ; Vidal R; Chan RJ; Goodwin CB; Hui SL; Peacock M; White KE
Proc Natl Acad Sci U S A; 2011 Nov; 108(46):E1146-55. PubMed ID: 22006328
[TBL] [Abstract][Full Text] [Related]
9. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice.
Clinkenbeard EL; Farrow EG; Summers LJ; Cass TA; Roberts JL; Bayt CA; Lahm T; Albrecht M; Allen MR; Peacock M; White KE
J Bone Miner Res; 2014 Feb; 29(2):361-9. PubMed ID: 23873717
[TBL] [Abstract][Full Text] [Related]
10. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.
ADHR Consortium
Nat Genet; 2000 Nov; 26(3):345-8. PubMed ID: 11062477
[TBL] [Abstract][Full Text] [Related]
11. FGF23 and disorders of phosphate homeostasis.
Yu X; White KE
Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
[TBL] [Abstract][Full Text] [Related]
12. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.
Bowe AE; Finnegan R; Jan de Beur SM; Cho J; Levine MA; Kumar R; Schiavi SC
Biochem Biophys Res Commun; 2001 Jun; 284(4):977-81. PubMed ID: 11409890
[TBL] [Abstract][Full Text] [Related]
13. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.
Imel EA; Peacock M; Gray AK; Padgett LR; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2011 Nov; 96(11):3541-9. PubMed ID: 21880793
[TBL] [Abstract][Full Text] [Related]
14. Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature.
Liu C; Zhao Z; Wang O; Li M; Xing X; Hsieh E; Fukumoto S; Jiang Y; Xia W
Calcif Tissue Int; 2019 Nov; 105(5):476-486. PubMed ID: 31486862
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
16. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.
Benet-Pagès A; Orlik P; Strom TM; Lorenz-Depiereux B
Hum Mol Genet; 2005 Feb; 14(3):385-90. PubMed ID: 15590700
[TBL] [Abstract][Full Text] [Related]
17. An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation.
Gribaa M; Younes M; Bouyacoub Y; Korbaa W; Ben Charfeddine I; Touzi M; Adala L; Mamay O; Bergaoui N; Saad A
J Bone Miner Metab; 2010; 28(1):111-5. PubMed ID: 19655082
[TBL] [Abstract][Full Text] [Related]
18. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
19. [Establishment of assay system for fibroblast growth factor (FGF)-23 and pathophysiological roles of FGF-23 in the development of hypophosphatemic diseases].
Fukumoto S; Nakahara K
Rinsho Byori; 2004 Jan; 52(1):51-4. PubMed ID: 14968560
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis.
Garringer HJ; Malekpour M; Esteghamat F; Mortazavi SM; Davis SI; Farrow EG; Yu X; Arking DE; Dietz HC; White KE
Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E929-37. PubMed ID: 18682534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
